Premium
The role of PET CT to evaluate the response to neoadjuvant chemotherapy in advanced breast cancer: Comparison with ultrasonography and magnetic resonance imaging
Author(s) -
Choi Jae Hyuck,
Lim Hye In,
Lee Se Kyung,
Kim Wan Wook,
Kim Sang Min,
Cho EunYoon,
Ko Eun Young,
Han BooKyung,
Park Yeon Hee,
Ahn JinSeok,
Im YoungHyuck,
Lee Jeong Eon,
Yang JungHyun,
Nam Seok Jin
Publication year - 2009
Publication title -
journal of surgical oncology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.201
H-Index - 111
eISSN - 1096-9098
pISSN - 0022-4790
DOI - 10.1002/jso.21424
Subject(s) - medicine , magnetic resonance imaging , breast cancer , radiology , nuclear medicine , neoadjuvant therapy , chemotherapy , ultrasound , cancer
Background Recently PET is emerged as a method to estimate the response of neoadjuvant chemotherapy (NAC) in advanced breast cancer. This study is aimed to estimate the predictive role of PET CT and other imaging modalities (ultrasound, MRI) through NAC. Methods PET CT was acquired before and after NAC from 41 patients. Pathologic results were classified as pathological complete response (pCR) and non‐pCR. The results of clinical responses were assessed with imaging indexes ( postTx , postchemotherapy size or peak standardized uptake values (pSUV); delta , the size difference between treatment; RR , reduction rate of tumor size or pSUV), and they were compared with pathologic results. Results Seven patients (17.1%) showed pCR. As a result of comparison of the image index, all image indexes of MRI were predictive for pCR ( P < 0.05). In contrast, only delta and RR of US, RR of PET CT were significant. The area under curve of delta and RR in MRI were higher (0.91, 0.90) than US (0.83, 0.80) and PET CT (0.62, 0.72). The MRI is superior to the US or PET CT. Conclusions We have concluded that the MRI is better than PET CT for monitoring the effect of NAC in advanced breast cancer. J. Surg. Oncol. 2010;102:392–397. © 2009 Wiley‐Liss, Inc.